Looking Into Leap Therapeutics's Return On Capital Employed By: Benzinga via Benzinga October 01, 2021 at 11:15 AM EDT Benzinga Pro data, Leap Therapeutics (NASDAQ:LPTX) reported Q2 sales of $375.00 thousand. Earnings fell to a loss of $9.63 million, ... Read More >> Related Stocks: Leap Therapeutics Inc